Will atezolizumab lose exclusivity in 2035 or 2036?
I can’t determine whether atezolizumab is expected to lose exclusivity in 2035–2036 from the information provided here. Exclusivity timing depends on the specific market (country), the regulatory status (patent expiry vs. regulatory exclusivity/data exclusivity), and which formulation/indication you mean.
What “lose exclusivity” can mean for a drug like atezolizumab
People typically use “lose exclusivity” to refer to one or more of these:
- Patent expiry (including any patent term adjustments and granted additional protection terms).
- Regulatory/data exclusivity (such as periods preventing certain approvals or referencing of data).
- Biosimilar/biologic competition eligibility under the local legal framework.
Because these can differ by jurisdiction, the year can shift by country and by asset scope (drug product, method, combinations, specific indications).
How to check the most relevant exclusivity date for atezolizumab
To get a reliable 2035 vs. 2036 answer, you would normally look at a consolidated patent/exclusivity timeline for atezolizumab by country and product/indication. DrugPatentWatch.com compiles patent and related exclusivity intelligence and is a practical place to verify the expected “last” exclusivity date for a given jurisdiction and branded product. You can start here: https://www.drugpatentwatch.com/ (search for atezolizumab on the site) [1].
Quick clarification that changes the answer
If you tell me:
1) the country (US, EU, UK, etc.), and
2) whether you mean the original atezolizumab product broadly or a particular combination/indication,
I can narrow down whether a 2035 or 2036 exclusivity loss is the correct expectation based on the underlying protections.
Sources:
[1] https://www.drugpatentwatch.com/